Form 4: Moderna Director Noubar Afeyan Sells Shares Worth Millions

Noubar Afeyan, a director at Moderna, sold a portion of his holdings in the company's common stock on May 22, 2024, under a pre-arranged trading plan.

Summary

• On May 22, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 9,662,114 shares are indirectly held by Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
• Additionally, 3,924 shares are indirectly held by Flagship Pioneering, Inc.
• The price per share varied across multiple transactions, ranging from $142.95 to $164.67.
• The total number of shares sold was not explicitly stated, but the transactions resulted in a decrease in Afeyan's direct holdings from 1,996,831 to 1,981,931 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, like a director, buys or sells shares of their company. It provides transparency to the market regarding the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency regarding insider transactions.
• Similar filings are made by executives and directors at companies like Pfizer, BioNTech, and Johnson & Johnson when they trade their company's stock.
• The use of a 10b5-1 trading plan is a common strategy for insiders to sell shares over time while avoiding accusations of trading on inside information; many executives at comparable companies use similar plans.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.
• However, the existence of a pre-arranged trading plan mitigates concerns about insider information being used for personal gain.

Key Dates